LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Kodu・Aktsiate loetelu・Savara Inc

Savara Inc

Avatud

SektorTervishoid

4.11 -4.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.13

Max

4.37

Põhinäitajad
By Trading Economics
Sissetulek	-3.8M -30M
Kasumimarginaal	-10,677.941
Töötajad	59
EBITDA	-1.9M -30M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+157.25% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. nov 2025

Turustatistika
By TradingEconomics
Turukapital	339M 805M
Eelmine avamishind	8.97
Eelmine sulgemishind	4.11

Uudiste sentiment

By Acuity

94%

363 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

2.76 / 2.84 Toetus ja vastupanu

Savara Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. nov 2025, 23:59 UTC

Tulu

Singtel's 1st Half Net Profit Surges

11. nov 2025, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11. nov 2025, 22:21 UTC

Tulu

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11. nov 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11. nov 2025, 23:44 UTC

Tulu

Singtel's 1H Net Profit Surges

11. nov 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11. nov 2025, 23:18 UTC

Tulu

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11. nov 2025, 23:15 UTC

Tulu

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11. nov 2025, 23:14 UTC

Tulu

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11. nov 2025, 23:12 UTC

Tulu

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11. nov 2025, 23:11 UTC

Tulu

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11. nov 2025, 23:10 UTC

Tulu

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11. nov 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. nov 2025, 21:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

11. nov 2025, 21:46 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11. nov 2025, 21:41 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11. nov 2025, 21:40 UTC

Tulu

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: Final Dividend 49 Australian Cents/Share

11. nov 2025, 21:37 UTC

Tulu

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11. nov 2025, 21:36 UTC

Tulu

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11. nov 2025, 21:35 UTC

Tulu

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Adj EPS 79c >ALC

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Rev $2.61B >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q EPS 48c >ALC.EB

Võrdlus sarnastega

Hinnamuutus

Savara Inc Prognoos

Hinnasiht

By TipRanks

157.25% tõus

12 kuu keskmine prognoos

Keskmine 10.29 USD 157.25%

Kõrge 16 USD

Madal 7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Savara Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Savara Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.76 / 2.84Toetus ja vastupanu

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

363 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.